



Cutting edge research into
Frontotemporal Dementia and Motor
Neurodegenerative Syndromes



RESCUEALS


Randomized, Double-Blind, Placebo-Controlled Study in
Early Symptomatic Amyotrophic Lateral Sclerosis Patients
on Stable Background Therapy to Assess Bioenergetic
Catalysis with CNM-Au8 to Slow Disease Progression in ALS

Matthew Kiernan



THE UNIVERSITY OF
SYDNEY

matthew.kiernan@sydney.edu.au




Disclosures & Acknowledgements

- MCK and the University of Sydney have received research funding from Clene to undertake Rescue-ALS
- We thank FightMND for its philanthropic support of the RESCUE-ALS study
- We thank the study participants and their families for their willingness to support clinical research



CNM-Au8[®] | Catalytically Active Au Nanocrystals Improve Cellular Energy Production

CNM-Au8[®]
Nanocrystal



Clean Surfaced, Highly Faceted Shape Enhances Catalytic Activity

Electrons (e⁻) Move Freely Across Nanocrystal Surface

Vertices, Edges, & Facets Key to Catalytic Activity

Mechanistic Effects

↑ Increased NAD

↑ Increased ATP

↓ Decreased reactive oxygen species

↑ Increased proteostasis

Increased Energy Production & Utilization

↑ Increased energetic potential




↑ Improved resistance to oxidative, mitochondrial, and excitotoxic stressors

↓ Reduction in levels of misfolded proteins



Design & Baseline Characteristics

36-Week Treatment Blinded Treatment with Long-Term Open-Label Follow-Up




Baseline Value mean (sd)	Age (yrs)	Sex n, (%) Male Female	Onset Site n, (%) Limb Bulbar	Months from Onset	FVC (% pred.)	ALSFRS-R Score	ENCALS Risk Score	MUNIX Sum
All (n=45)	59.1 (12.3)	M: 26 (58%) F: 19 (42%)	L: 33 (73%) B: 12 (27%)	15.8 (9.3)	81.5 (16.7)	38.7 (6.0)	-4.4 (1.8)	378.2 (175.3)
CNM-Au8 30mg (n=23)	57.0 (13.3)	M: 13 (57%) F: 10 (43%)	L: 16 (70%) B: 7 (30%)	15.5 (7.6)	84.5 (18.3)	38.6 (6.6)	-4.6 (1.7)	380.2 (198.0)
Placebo (n=22)	61.3 (10.9)	M: 13 (59%) F: 9 (41%)	L: 17 (77%) B: 5 (23%)	16.1 (10.9)	78.2 (14.5)	38.8 (5.4)	-4.2 (1.8)	376.2 (152.7)


Significant slowing in disease progression & ALSFRS-R 6-point decline



Significant improvement in quality of life





Long-Term Survival in OLE Participants: 70% Improvement vs. Predicted Survival



- All OLE participants. Data censored as of 10-March-2022. Vital status and date of death (as applicable) captured for all subjects withdrawn from the study. ENCALS median survival estimate from baseline characteristics.

Consistent Survival Effect in ex-Placebo Participants



- All OLE participants. Data censored as of 10-March-2022. Vital status and date of death (as applicable) captured for all subjects withdrawn from the study. ENCALS median survival estimate from baseline characteristics.

Conclusions

- Well tolerated and safe in ALS
- Evidence of CNM-Au8 therapeutic activity:
 - Evidence for improved survival
 - Significant reduction in functional decline
 - Significant slowing in disease progression
 - Improvement in quality of life